

North Central Cancer Treatment Group

N0177: A Phase I/II Trial of OSI-774 and Temozolomide in Combination with Radiation Therapy in Glioblastoma Multiforme

Status Change – February 7, 2006

NOTICE OF STATUS CHANGE

Study 2 will open to accrual for 1 additional EAC patient at dose level 2E (450 mg OSI-774) effective immediately, Tuesday, February 07, 2006.

Please retain this notice with the protocol.